Ractigen Therapeutics Reports First-In-Human RNA Activation Data

Shanghai, China, September 16, 2026

RNA Activation Approach Targets DMD Biology

Duchenne muscular dystrophy is an X-linked genetic disorder characterized by progressive muscle degeneration and weakness. The disease is primarily caused by mutations in the DMD gene that disrupt production of functional dystrophin, a protein essential for maintaining the structural integrity of muscle fibers. As the disease progresses, patients can experience substantial loss of mobility and complications affecting respiratory and cardiac function. Ractigen is developing RNA activation technology as a potential strategy for treating genetic diseases. RNAa is designed to increase the expression of specific genes by using small RNA molecules to activate transcription. In the context of DMD, the approach is being investigated as a way to influence gene expression and potentially address disease mechanisms at the molecular level. The company’s platform differs from conventional RNA interference approaches, which generally reduce the expression of target genes. Instead, RNA activation seeks to increase expression of selected genes, creating a potential therapeutic strategy for disorders in which restoring or increasing beneficial gene activity may be relevant.

First-In-Human Data Mark Clinical Milestone

The late-breaking presentation at the World Muscle Society Congress will provide an opportunity to share first-in-human data from Ractigen’s DMD program with the international neuromuscular research community. First-in-human studies are designed to generate initial information about how an investigational therapy behaves in people, including assessments related to safety, tolerability, pharmacokinetics, pharmacodynamics, and biological activity, depending on the study design. The transition into human testing is a significant step for any emerging therapeutic platform. Preclinical studies can establish biological activity and provide evidence supporting clinical development, but human studies are required to determine whether those findings translate into patients. The upcoming Ractigen presentation is therefore expected to provide additional insight into the clinical development of RNA activation technology in DMD. The company has positioned the program as part of its broader effort to develop RNA-based medicines for serious genetic and neurological diseases. Presenting the findings as a late-breaking oral presentation also places the research within a scientific forum focused specifically on muscle and neuromuscular disorders.

World Muscle Society Presentation Advances RNA Research

The 31st Annual Congress of the World Muscle Society brings together researchers and clinicians involved in neuromuscular disease research, providing a platform for discussion of emerging therapeutic approaches. Ractigen’s late-breaking presentation will focus on its first-in-human RNA activation findings in DMD, adding clinical information to the growing body of research surrounding RNA-based therapies. RNA therapeutics have become an increasingly important area of biopharmaceutical innovation, with researchers investigating multiple RNA modalities for genetic and acquired diseases. Approaches including RNA interference, antisense oligonucleotides, messenger RNA, and RNA activation are being explored to modify disease-associated biological pathways.

For DMD, researchers continue to investigate strategies aimed at restoring dystrophin production or otherwise modifying the molecular consequences of DMD mutations. RNA activation represents a different mechanism within this broader landscape, and clinical data will be important for determining its potential advantages, limitations, and future development requirements. Ractigen’s upcoming presentation therefore represents a significant clinical-development milestone for the company and its RNA activation platform. The first-in-human findings may provide important information about the feasibility of applying RNAa technology to DMD and could help guide subsequent studies. As the program progresses, additional clinical research will be needed to establish the safety, biological activity, and potential therapeutic efficacy of the approach. The presentation also highlights the continuing evolution of RNA therapeutics for rare genetic diseases, with innovative modalities moving from laboratory research toward clinical testing. For the DMD research community, the emergence of new molecular approaches could expand the range of strategies being investigated for this challenging neuromuscular disorder.

Source: Ractigen Therapeutics press release